SLC5A2 and type 2 diabetes mellitus: In a 2024 study [43], despite the well-known cardiovascular benefits observed in the general population with T2DM and in other patient groups regardless of diabetes status, current evidence does not support the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors in the context of ACS.